Form 4: Tarsus CHRO Sells Shares Under 10b5-1 Plan

Tarsus Pharmaceuticals' Chief Human Resources Officer, Dianne C. Whitfield, sold common stock totaling 15,565 shares on January 2, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, Inc. (TARS), reported sales of common stock.
• The transactions occurred on January 2, 2026, and involved a total of 15,565 shares of common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted by Ms. Whitfield on September 12, 2025.
• Shares were sold at weighted average prices ranging from $80.09 to $82.93 per share.
• Specifically, 5,715 shares were sold at a weighted average price of $80.09 (ranging from $79.42 to $80.40).
• Another 8,122 shares were sold at a weighted average price of $80.71 (ranging from $80.42 to $81.29).
• An additional 835 shares were sold at a weighted average price of $81.90 (ranging from $81.68 to $82.62).
• Finally, 893 shares were sold at a weighted average price of $82.93 (ranging from $82.82 to $83.32).
• Following these transactions, Ms. Whitfield's direct beneficial ownership of common stock decreased to 23,393 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it reports insider selling, the transactions were pre-planned under a 10b5-1 plan, which is a routine and expected practice for executives managing their personal finances and equity compensation, thus mitigating any negative implications typically associated with insider sales.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled transactions rather than reactive selling based on immediate, non-public information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by investors as a lack of confidence, though this is mitigated by the 10b5-1 plan.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales reported were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

Industry Context

Insider transactions, particularly sales by executives, are a common occurrence in publicly traded companies. The use of a Rule 10b5-1 trading plan is standard practice for corporate insiders to manage their equity holdings and avoid accusations of trading on material non-public information, aligning with best practices in corporate governance.

Corporate Governance

Stakeholder Impact

• Shareholders may observe the reduction in an executive's direct ownership, but the pre-planned nature of the sales under a 10b5-1 plan typically minimizes concerns about opportunistic trading.

Key Dates

Recommendation

The filing details routine insider stock sales executed under a pre-arranged 10b5-1 trading plan. Such transactions are common for executives managing their personal finances and equity compensation and do not typically indicate a change in the company's fundamental outlook or warrant a shift in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Tarsus Pharmaceuticals, TARS, Insider Trading, Form 4, 10b5-1 Plan, Stock Sale, Executive Compensation, Chief Human Resources Officer